When.com Web Search

Search results

  1. Results From The WOW.Com Content Network
  2. Aflibercept - Wikipedia

    en.wikipedia.org/wiki/Aflibercept

    Common adverse effects of the eye formulation include conjunctival hemorrhage, eye pain, cataract, vitreous detachment, floaters, and ocular hypertension. [13]Aflibercept (Zaltrap) has adverse effects typical of anti-cancer drugs, such as reduced blood cell count (leukopenia, neutropenia, thrombocytopenia), gastrointestinal disorders like diarrhea and abdominal pain, and fatigue.

  3. Macular degeneration - Wikipedia

    en.wikipedia.org/wiki/Macular_degeneration

    The incidence of age-related macular degeneration and its associated features increases with age and is low in people <55 years of age. [101] Smoking is the strongest modifiable risk factor. [102] As of 2008, age-related macular degeneration accounts for more than 54% of all vision loss in the white population in the US. [103]

  4. Intravitreal injection - Wikipedia

    en.wikipedia.org/wiki/Intravitreal_injection

    Intravitreal injection was first mentioned in a study in 1911, in which the injection of air was used to repair a detached retina. [6] [7] [8] There were also investigations evaluating intravitreal antibiotics injection using sulfanilamide and penicillin to treat endophthalmitis in the 1940s, yet due to the inconsistency of results and safety concerns, this form of drug delivery was only for ...

  5. FDA Approves Biosimilars for Macular Degeneration Treatment - AOL

    www.aol.com/lifestyle/fda-approves-biosimilars...

    The FDA approved two interchangeable biosimilars to treat macular degeneration. The biosimilars work the same way as Eylea which prevents abnormal blood vessel growth in the eye and helps preserve ...

  6. Stem cell therapy for macular degeneration - Wikipedia

    en.wikipedia.org/wiki/Stem_cell_therapy_for...

    Induced pluripotent stem cell taken from blood cell and converted in retinal pigment epithelium. Stem cell therapy for macular degeneration is an emerging treatment approach aimed at restoring vision in individuals suffering from various forms of macular degeneration, particularly age-related macular degeneration (AMD). [1]

  7. Anti-VEGF - Wikipedia

    en.wikipedia.org/wiki/Anti-VEGF

    It was concluded from the two-year, phase III study that ranibizumab is very effective in the treatment of minimally classic (MC) or occult wet AMD (age-related macular degeneration) with low rates of ocular adverse effects. [8] Another study published in the January 2009 issue of Ophthalmology provides the evidence for the efficacy of ranibizumab.

  8. Geographic atrophy - Wikipedia

    en.wikipedia.org/wiki/Geographic_atrophy

    Fundus of geographic atrophy. Geographic atrophy (GA), also known as atrophic age-related macular degeneration (AMD) or advanced dry AMD, is an advanced form of age-related macular degeneration that can result in the progressive and irreversible loss of retinal tissue (photoreceptors, retinal pigment epithelium, choriocapillaris) which can lead to a loss of central vision over time.

  9. Posterior vitreous detachment - Wikipedia

    en.wikipedia.org/wiki/Posterior_vitreous_detachment

    The risk of retinal detachment is the greatest in the first 6 weeks following a vitreous detachment, but can occur over 3 months after the event.. The risk of retinal tears and detachment associated with vitreous detachment is higher in patients with myopic retinal degeneration, lattice degeneration, and a familial or personal history of previous retinal tears/detachment.